(Q42703628)

5 November 2017

title

Resveratrol prevents pathological but not physiological cardiac hypertrophy (English)

1 reference

5 November 2017

Vernon W Dolinsky

1

1 reference

5 November 2017

Carrie-Lynn M Soltys

2

1 reference

5 November 2017

Kyle J Rogan

3

1 reference

5 November 2017

Anita Y M Chan

4

1 reference

5 November 2017

Jeevan Nagendran

5

1 reference

5 November 2017

Shaohua Wang

6

1 reference

5 November 2017

Jason R B Dyck

7

1 reference

5 November 2017

publication date

15 November 2014

1 reference

Journal of Molecular Medicine

5 November 2017

published in

1 reference

5 November 2017

volume

93

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

413-425

1 reference

Left ventricular hypertrophy: pathogenesis, detection, and prognosis

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Cardiac hypertrophy: a matter of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Role of AMP-activated protein kinase in healthy and diseased hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Continued postnatal administration of resveratrol prevents diet-induced metabolic syndrome in rat offspring born growth restricted.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

New insights into the importance of aminopeptidase A in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol improves health and survival of mice on a high-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1220-8

Resveratrol Arrests and Regresses the Development of Pressure Overload- but Not Volume Overload-Induced Cardiac Hypertrophy in Rats

21 January 2018

1 reference

12 December 2020

Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy

1 reference

12 December 2020

Effect of growth hormone administration and treadmill exercise on the body composition of rats

1 reference

12 December 2020

Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol

1 reference

12 December 2020

Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats

1 reference

12 December 2020

Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model

1 reference

12 December 2020

10.1007/S00109-014-1220-8

Identifiers

DOI

1 reference

5 November 2017

1 reference